Conference Details - Overview

View all Conferences

Continuing Education Information

Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit™

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Optimizing Adjuvant Endocrine Therapy: Where Do We Stand in 2008?

Grand Hyatt Kauai
Koloa, HI
July 23, 2008

Conference Overview

The Optimizing Adjuvant Endocrine Therapy: Where Do We Stand in 2008? symposium will cover the latest information on endocrine therapy for breast cancer in the adjuvant setting, including current clinical data on alternate strategies for the use of aromatase inhibitors, such as up-front treatment, switching after 2-3 years, and extended therapy beyond 5 years. The symposium will also address the role of pharmacogenetics in treatment decisions, specifically focusing on CYP2D6 or other enzymes and tamoxifen metabolism. Case-based presentations and a panel discussion will stimulate discussion concerning controversial clinical issues. This educational program is directed toward medical, radiation, and surgical oncologists with an interest in the treatment of breast cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows, oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of breast cancer are also invited to attend. At the conclusion of this symposium, you should be able to:

• Assess the ongoing risk of recurrence for patients with hormone receptor–positive breast cancer and the implications for adjuvant endocrine therapy strategies

• Compare the efficacy/safety of up-front aromatase inhibitor therapy to that of tamoxifen/aromatase inhibitor switching or sequencing strategies in the adjuvant setting

• Discuss the effects of polymorphisms in CYP2D6 or other metabolic enzymes and of drugs that inhibit CYP2D6 activity on tamoxifen metabolism and their implications for treatment decisions for patients with hormone receptor–positive breast cancer

• Discuss the rationale for extended adjuvant endocrine therapy and recent data from trials investigating different durations of therapy

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology